Shintaro Maeda

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Interstitial Lung Disease

Systemic Sclerosis

Clinical Practice

Top Venues

The Journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Natsumi Fushida, Motoki Horii, Ko Fujii, Kie Mizumaki, Tasuku Kitano, Kaori Sawada, Natsuki Numata, Kyosuke Oishi, Shintaro Maeda, Yasuhito Hamaguchi, Satoshi Watanabe, Takashi Matsushita
Clinical features of patients with connective tissue disease with anti-human upstream binding factor antibodies: A single-center retrospective study. The Journal of dermatology 51 (5) (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 51 (4) (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 51 (4) (2024)
Natsumi Fushida, Motoki Horii, Ko Fujii, Kie Mizumaki, Tasuku Kitano, Kaori Sawada, Natsuki Numata, Kyosuke Oishi, Shintaro Maeda, Yasuhito Hamaguchi, Satoshi Watanabe, Takashi Matsushita
Clinical features of patients with connective tissue disease with anti-human upstream binding factor antibodies: A single-center retrospective study. The Journal of dermatology (2024)
Natsumi Fushida, Motoki Horii, Ko Fujii, Kie Mizumaki, Tasuku Kitano, Kaori Sawada, Natsuki Numata, Kyosuke Oishi, Shintaro Maeda, Yasuhito Hamaguchi, Satoshi Watanabe, Takashi Matsushita
Clinical features of patients with connective tissue disease with anti-human upstream binding factor antibodies: A single-center retrospective study. The Journal of dermatology 51 (5) (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 51 (4) (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 51 (4) (2024)
Toshihiko Hoashi, Masashi Ishikawa, Jiro Uehara, Kohei Oashi, Shintaro Maeda, Junji Kato, Hiroshi Saruta, Ryuji Shichinohe, Ryuji Ohashi, Yoshio Nakamura, Hiroshi Koga, Makoto Sugaya, null null
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 51 (4) (2024)
Yasuhito Hamaguchi, Yukari Yoshimura, Motoki Horii, Natsumi Fushida, Tasuku Kitano, Kaori Sawada, Kyosuke Oishi, Shintaro Maeda, Satoshi Watanabe, Takashi Matsushita
Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody. The Journal of dermatology (2023)
Kie Mizumaki, Satoshi Makino, Yuka Ikawa, Shintaro Maeda, Motoki Horii, Natsumi Fushida, Yasuhito Hamaguchi, Takahiro Nohara, Koji Izumi, Takashi Matsushita
Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody. The Journal of dermatology 49 (9) (2022)